GlassScriptPhysician profile
Camille A Watson
NPI 1811096324
$34,102.90
in general payments reported to CMS, 2019-2025
26 companies · $2,985 in 2025
The $2,985 reported for 2025 was more than what 93% of Psychiatric/Mental Health (Clinical Nurse Specialist) providers received nationally (typical 2025 total: $244).
See the full distribution for Psychiatric/Mental Health (Clinical Nurse Specialist)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $5,002 · 2022: $7,869 · 2023: $16K · 2024: $2,573 · 2025: $2,985.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $12K · Food and Beverage: $8,866 · Travel and Lodging: $595 · Education: $8.93.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $11,761.00 |
| Food and Beverage | $8,866.46 |
| Travel and Lodging | $595.34 |
| Education | $8.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $14,049.55 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $9,594.99 | 2021-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Alkermes, INC. | $2,489.70 | 2021-2025 | Aristada, Lybalvi, Aristada Initio |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,875.69 | 2021-2025 | Caplyta |
| Lundbeck LLC | $1,102.37 | 2021-2025 | Rexulti, Abilify Maintena |
| Takeda Pharmaceuticals U.S.A., INC. | $788.82 | 2021-2025 | Trintellix |
| Axsome Therapeutics, INC. | $608.08 | 2023-2025 | Auvelity, Sunosi |
| Neurocrine Biosciences, INC. | $499.21 | 2021-2025 | Ingrezza |
| Ironshore Pharmaceuticals INC. | $467.76 | 2021-2024 | Jornay Pm |
| Sunovion Pharmaceuticals INC. | $439.29 | 2021-2022 | |
| Corium, LLC | $431.86 | 2022-2025 | Azstarys |
| Teva Pharmaceuticals USA, INC. | $430.85 | 2021-2025 | Austedo Xr, Uzedy, Austedo Xr |
| E.R. Squibb & Sons, L.L.C. | $246.24 | 2025 | Cobenfy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $229.50 | 2023-2025 | |
| Noven Therapeutics, LLC | $131.37 | 2023-2025 | Xelstrym, Secuado |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $121.38 | 2023 | |
| Eisai INC. | $87.08 | 2021-2022 | |
| Supernus Pharmaceuticals, INC. | $83.69 | 2022-2023 | Qelbree |
| Collegium Pharmaceutical, INC. | $82.03 | 2025 | Jornay Pm |
| Idorsia Pharmaceuticals US INC | $80.76 | 2023-2024 | Quviviq |
| Neos Therapeutics, LP | $73.90 | 2021-2024 | Adzenys Xr-Odt |
| Janssen Pharmaceuticals, INC | $51.02 | 2021-2023 | Spravato |
| Jazz Pharmaceuticals INC. | $40.70 | 2021 | |
| Tris Pharma INC | $38.37 | 2022-2024 | Dyanavel Xr |
| Alfasigma USA, INC. | $31.51 | 2022 | |
| Acadia Pharmaceuticals INC | $27.18 | 2025 | Nuplazid |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Camille Watson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.